Your browser is no longer supported. Please, upgrade your browser.
SBPH Spring Bank Pharmaceuticals, Inc. daily Stock Chart
Spring Bank Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-1.75 Insider Own0.60% Shs Outstand17.05M Perf Week-2.88%
Market Cap24.57M Forward P/E- EPS next Y-0.79 Insider Trans0.00% Shs Float15.85M Perf Month7.14%
Income-29.10M PEG- EPS next Q-0.25 Inst Own28.60% Short Float0.59% Perf Quarter-12.34%
Sales- P/S- EPS this Y7.90% Inst Trans-0.72% Short Ratio0.39 Perf Half Y40.63%
Book/sh1.36 P/B0.99 EPS next Y43.60% ROA-52.90% Target Price1.75 Perf Year-56.87%
Cash/sh1.29 P/C1.05 EPS next 5Y- ROE-89.80% 52W Range0.80 - 4.80 Perf YTD-14.56%
Dividend- P/FCF- EPS past 5Y-1.30% ROI- 52W High-71.88% Beta0.98
Dividend %- Quick Ratio5.10 Sales past 5Y- Gross Margin- 52W Low68.75% ATR0.10
Employees30 Current Ratio5.10 Sales Q/Q- Oper. Margin- RSI (14)42.47 Volatility4.93% 8.25%
OptionableNo Debt/Eq0.00 EPS Q/Q-38.50% Profit Margin- Rel Volume0.21 Prev Close1.28
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume236.83K Price1.35
Recom3.00 SMA20-1.17% SMA50-10.20% SMA200-11.50% Volume50,282 Change5.47%
Jan-30-20Downgrade Jefferies Buy → Hold $28 → $1.50
Dec-30-19Downgrade B. Riley FBR Buy → Neutral $16 → $2
Oct-09-18Initiated Jefferies Buy
Feb-21-18Reiterated Cantor Fitzgerald Overweight $29 → $32
Nov-06-17Initiated B. Riley FBR, Inc. Buy $30
Aug-01-17Reiterated Chardan Capital Markets Buy $34 → $30
Jul-20-17Initiated Cantor Fitzgerald Overweight $29
May-24-17Reiterated Chardan Capital Markets Buy $16.50 → $34
May-19-17Initiated JMP Securities Mkt Outperform $20
May-02-17Initiated Chardan Capital Markets Buy $16.50
Sep-23-20 11:50PM  
Sep-22-20 06:45PM  
Sep-21-20 03:20PM  
Sep-20-20 12:30PM  
Sep-17-20 02:55PM  
Sep-09-20 08:30PM  
Sep-03-20 03:11AM  
Sep-01-20 07:38PM  
Aug-27-20 04:35PM  
Aug-26-20 06:39PM  
Aug-22-20 07:35AM  
Aug-20-20 02:03PM  
Aug-18-20 04:11PM  
Aug-17-20 07:00PM  
Aug-15-20 07:00AM  
Aug-13-20 09:00PM  
Aug-11-20 12:10PM  
Aug-10-20 06:50PM  
Aug-08-20 10:15PM  
Aug-06-20 06:58PM  
Aug-04-20 09:42AM  
Aug-03-20 10:40PM  
Aug-01-20 10:05AM  
Jul-31-20 01:35PM  
Jul-30-20 06:50PM  
Jul-29-20 04:27PM  
Jun-04-20 10:12PM  
Jun-03-20 08:00AM  
May-26-20 04:30PM  
May-20-20 07:00AM  
May-07-20 04:30PM  
Apr-02-20 08:00AM  
Mar-30-20 09:30AM  
Feb-25-20 08:00AM  
Feb-14-20 09:37AM  
Jan-29-20 08:40AM  
Dec-30-19 09:53AM  
Dec-27-19 10:02AM  
Dec-26-19 02:09PM  
Dec-24-19 10:30AM  
Dec-17-19 05:04PM  
Dec-13-19 08:36AM  
Dec-11-19 08:56AM  
Dec-09-19 08:00AM  
Nov-28-19 05:26AM  
Nov-20-19 09:00AM  
Nov-12-19 08:00AM  
Nov-07-19 04:30PM  
Oct-17-19 08:00AM  
Oct-01-19 12:07PM  
Sep-23-19 08:00AM  
Sep-17-19 08:00AM  
Sep-04-19 08:00AM  
Aug-06-19 08:00AM  
Jul-31-19 04:30PM  
Jul-29-19 08:00AM  
Jul-23-19 08:34AM  
Jul-22-19 10:36AM  
Jul-18-19 11:00AM  
Jul-10-19 04:00PM  
Jul-01-19 08:00AM  
Jun-27-19 08:30AM  
Jun-06-19 08:00AM  
May-28-19 08:00AM  
May-24-19 07:39AM  
Apr-29-19 07:00AM  
Apr-12-19 06:00AM  
Apr-10-19 04:01PM  
Mar-28-19 08:00AM  
Mar-14-19 08:00AM  
Mar-13-19 11:39PM  
Mar-11-19 06:30AM  
Mar-04-19 04:01PM  
Feb-19-19 04:38PM  
Dec-18-18 04:15PM  
Dec-06-18 07:00AM  
Nov-29-18 08:00AM  
Nov-09-18 08:00AM  
Nov-05-18 08:00AM  
Nov-01-18 08:00AM  
Oct-29-18 11:00AM  
Oct-25-18 04:30PM  
Spring Bank Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for the treatment of a range of cancers and inflammatory diseases using its proprietary small molecule nucleotide platform. The company is developing SB 11285, a next-generation immunotherapeutic cyclic dinucleotide for the treatment of selected cancers; novel STING antagonist compounds for the treatment of autoimmune and inflammatory diseases; and novel platform to enable the targeted delivery of payload molecules. It has a collaboration agreement with with Roche to explore the co-administration of SB 11285. The company was formerly known as Spring Bank Technologies, Inc. and changed its name to Spring Bank Pharmaceuticals, Inc. in May 2008. Spring Bank Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Hopkinton, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Eichler Kurt MDirectorDec 30Sale1.2640,00050,540549,273Jan 02 05:16 PM
Freve JonathanCFO & TreasurerNov 14Buy3.045,00015,20017,482Nov 14 04:08 PM
Driscoll Martin JPresident and CEONov 13Buy2.835,00014,15090,400Nov 14 08:46 AM